Loading...
Loading...
TNYA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 26.7M |
| Operating I/L | -26.7M |
| Other Income/Expense | 1.1M |
| Interest Income | 1.1M |
| Pretax | -25.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -25.6M |
Tenaya Therapeutics, Inc. is a biotechnology company specializing in developing and delivering therapies for heart disease. The company's focus is on cellular regeneration, gene therapy, and precision medicine platforms. Its product pipeline includes TN-201, an adeno-associated virus (AAV)-based gene therapy for genetic hypertrophic cardiomyopathy (gHCM); TN-301, a small molecule inhibitor for heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM); and TN-401, an AAV-based gene therapy for genetic arrhythmogenic right ventricular cardiomyopathy (gARVC). Additionally, the company is working on AAV-based gene therapies for DCM and a reprogramming program for cardiac regeneration.
